NASDAQ$PRTA

Prothena Corporation plc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Reported financial results for the third quarter and first nine months of 2023 and provided business highlights.

Prothena reported a net income of $21.9 million for the third quarter of 2023, a significant increase compared to a net loss of $45.8 million for the same period in 2022. The company's total revenue reached $84.9 million, primarily driven by collaboration revenue from Bristol Myers Squibb, including a $55 million payment for the exclusive worldwide license to PRX005. As of September 30, 2023, Prothena's cash and restricted cash position was $673.1 million.

  • Net income was $21.9 million, compared to a net loss of $45.8 million in Q3 2022.
  • Revenue reached $84.9 million, primarily from collaboration revenue from Bristol Myers Squibb.
  • Received $55 million payment from Bristol Myers Squibb for exclusive worldwide license to PRX005.
  • Cash and restricted cash position was $673.1 million at the end of the quarter.

Headline financials

Total Revenue

$84.9M

Previous: $1.52M+5494.3%
EPS (adj)

$0.38

Previous: -$0.97+139.2%
Capital Expenditures

-$1.26M

Previous: -$313K-302.9%
Free Cash Flow

$20.6M

Previous: -$46.1M+144.8%
Net Income

$21.9M

Previous: -$45.8M+147.9%
Operating Income

$10.3M

Previous: -$50.3M+120.5%
Gross Profit

$82.6M

Previous: $700K+11693.3%
Cash & Equivalents

$671M

Previous: $496M+35.4%
Total Assets

$747M

Previous: $554M+34.7%
R&D Expense

$57.9M

No prior period
Stock-Based Comp

$10.9M

Previous: $7.97M+37.4%

Revenue & EPS history

Prothena · Revenue · Quarterly

$84.9M

Q3 2023+5,494.3%vs Q3 2022
Beat estimate in 3 of 14 quarters(21%)
ActualEstimate

Revenue by segment

Prothena · $84.9M total across 1 segment · Q3 2023

  • Collaboration Revenue
    $84.9M+5557.7%

Forward guidance

The Company continues to expect the full year 2023 net cash used in operating and investing activities to be $148 to $161 million and expects to end the year with approximately $600 million in cash, cash equivalents and restricted cash (midpoint).

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+1.5%

Avg return

Earnings day

+0.4%

Avg return

5 days after

+0.2%

Avg return

30 days after

57%

30 / 53 earnings

Positive

+45.3%

Q4 2020

Best reaction

-12.0%

Q1 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.1%-8.7%-16.5%
Q4 2025-0.2%-1.7%-3.1%
Q3 2025+5.2%+7.6%+9.8%
Q1 2025+5.2%-3.0%-23.8%
Q4 2024+2.0%-4.6%-15.0%
Q3 2024-4.7%-22.5%-23.6%
Q2 2024+6.7%+3.7%+5.6%
Q1 2024-6.5%-12.0%-10.2%
Q4 2023+2.7%+0.9%-4.5%
Q3 2023+2.4%-0.7%-4.9%
Q2 2023-8.7%-9.7%-18.3%
Q1 2023+17.2%+13.0%+2.9%
Q4 2022+4.6%+7.0%-9.7%
Q3 2022-8.8%-6.6%+8.6%
Q2 2022-8.5%-2.8%-19.1%
Q1 2022-4.7%-13.7%-12.0%
Q4 2021-9.6%-8.3%+5.1%
Q3 2021-0.7%-4.8%-21.5%
Q2 2021+5.0%+5.8%+30.5%
Q1 2021-6.6%-1.8%+90.3%
Q4 2020+45.3%+46.2%+46.5%
Q3 2020+20.9%+7.3%+1.5%
Q2 2020+3.5%+1.5%+8.2%
Q1 2020-7.9%-0.8%-11.7%
Q4 2019-0.1%+0.9%-22.7%
Q3 2019-3.1%-3.0%+32.7%
Q2 2019+2.4%-2.2%-1.3%
Q1 2019+2.7%-1.9%-16.2%
Q4 2018+3.1%+4.3%+12.5%
Q3 2018+0.6%-4.1%-9.8%
Q2 2018+2.7%+8.2%+3.6%
Q1 2018-2.4%+13.1%-1.2%
Q4 2017+8.0%+11.6%+18.1%
Q3 2017-9.2%-8.6%-34.4%
Q2 2017-4.2%-7.1%-1.3%
Q1 2017+11.2%+12.2%+3.2%
Q4 2016+1.4%+5.9%+3.9%
Q3 2016-5.6%-8.3%+14.3%
Q2 2016+2.8%+2.3%-7.9%
Q1 2016-12.0%
Q4 2015+1.4%
Q3 2015+10.9%
Q2 2015-1.1%
Q1 2015-8.5%
Q4 2014-0.2%
Q3 2014-6.0%
Q2 2014+12.2%
Q1 2014+1.0%
Q4 2013+0.5%
Q3 2013+4.7%
Q2 2013-1.6%
Q1 2013+11.9%
Q4 2012+0.6%
Q3 2012
Q2 2012
Q1 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro